Mallinckrodt (MNK) Proxy Filing summary

Executive summary

• An extraordinary general meeting (EGM) is scheduled for October 8, 2025, to vote on key corporate changes, including a company name change and significant share capital restructuring.

• The Board of Directors unanimously recommends voting in favor of all proposed resolutions, which aim to rebrand the company and provide flexibility for future corporate actions.

• Shareholders of record as of September 5, 2025, are eligible to vote, with multiple voting methods available, including online, phone, mail, or in person.

• The EGM will be held in Dublin, Ireland, and proxy materials are accessible online and by request.

Voting matters and shareholder proposals

• Resolution 1 seeks approval to change the company name to Keenova Therapeutics plc, requiring a 75% majority as a special resolution.

• Resolution 2(a) and 2(b) propose sub-dividing and increasing authorized preferred share capital to 3 trillion shares at $0.001 par value, requiring a simple majority.

• Resolution 3 authorizes adjournment of the EGM if more time is needed to solicit votes, also requiring a simple majority.

• The Board recommends voting "FOR" all resolutions.

Board of directors and corporate governance

• Directors and executive officers collectively own approximately 0.14% of outstanding shares and intend to vote in favor of all proposals.

• Shareholder proposals for the 2026 Annual General Meeting must be submitted by December 4, 2025, for inclusion in the proxy statement.